Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

This study has been completed.
Sponsor:
Collaborator:
Onyx Pharmaceuticals
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00110994
First received: May 16, 2005
Last updated: May 13, 2015
Last verified: May 2015
Results First Received: January 26, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Cancer
Melanoma
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Placebo
Drug: Dacarbazine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A total of 121 subjects were enrolled at 17 centers in the United States. There were 20 screening failures; 12 subjects did not meet 1 or more entry criteria, 4 subjects withdrew consent before randomization, and 4 subjects were not randomized for other reasons. 101 subjects were randomized between 21 Mar 2005 and 27 Apr 2006.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 101 subjects were randomized (50 to Placebo + Dacarbazine (DTIC) and 51 to Sorafenib + DTIC) and were included in the population valid for intent to treat (ITT) analyses. All randomized subjects received study drug and were included in the population valid for safety analyses.

Reporting Groups
  Description
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
Placebo + Dacarbazine Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.

Participant Flow for 3 periods

Period 1:   Double-blind (DB) Treatment
    Sorafenib (Nexavar, BAY43-9006) + Dacarbazine   Placebo + Dacarbazine
STARTED   51 [1]   50 [1] 
Received Treatment   51 [2]   50 [2] 
COMPLETED   9   3 
NOT COMPLETED   42   47 
Adverse Event                3                0 
Death                1                0 
Withdrawal by Subject                0                2 
Progression by clinical judgement                2                1 
Radiological and symptomatic progression                34                41 
other reasons                2                3 
[1] ITT population
[2] Safety population

Period 2:   Active Follow-up
    Sorafenib (Nexavar, BAY43-9006) + Dacarbazine   Placebo + Dacarbazine
STARTED   1 [1]   2 [1] 
COMPLETED   0   0 
NOT COMPLETED   1   2 
Disease progression/recurrence/replace                1                0 
Other reasons                0                2 
[1] Subjects discontinued DB treatment with CR, PR and SD entered this period.

Period 3:   Long Term Follow-up
    Sorafenib (Nexavar, BAY43-9006) + Dacarbazine   Placebo + Dacarbazine
STARTED   41 [1]   47 [1] 
COMPLETED   22   30 
NOT COMPLETED   19   17 
Death                19                17 
[1] Subjects discontinued DB treatment with DP entered this period.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
Placebo + Dacarbazine Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
Total Total of all reporting groups

Baseline Measures
   Sorafenib (Nexavar, BAY43-9006) + Dacarbazine   Placebo + Dacarbazine   Total 
Overall Participants Analyzed 
[Units: Participants]
 51   50   101 
Age 
[Units: Years]
Mean (Standard Deviation)
 56.5  (12.7)   60.1  (13.8)   58.3  (13.3) 
Age, Customized 
[Units: Participants]
     
<65 years   36   33   69 
>=65 and <75 years   11   8   19 
>=75 years   4   9   13 
Gender 
[Units: Participants]
     
Female   13   17   30 
Male   38   33   71 
American Joint Committee on Cancer (AJCC) Stage at Study Entry [1] 
[Units: Participants]
     
Stage III   2   1   3 
Stage IV M1a   3   7   10 
Stage IV M1b   18   17   35 
Stage IV M1c   28   25   53 
[1] Stage III: Clinical or radiological evidence of regional metastases (M), in either the lymph nodes or intra-lymphatic. Stage IV: M at any distant site. M1a: M to the skin, subcutaneous tissue, or lymph nodes. M1b: M to the lung. M1c: M to all other visceral sites or at any site associated with an elevated serum lactate dehydrogenase.
Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status [1] 
[Units: Participants]
     
Status 0   31   31   62 
Status 1   20   19   39 
[1] Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects a patient. The scale ranges from 0 (fully active) to 5 (dead). Subjects entering this study must have had an ECOG score of 0 or 1 (restricted in physically strenuous activity but ambulatory).
Lactate dehydrogenase (LDH) at study entry [1] 
[Units: Participants]
     
Normal   33   29   62 
Low   1   2   3 
High   12   17   29 
Missing   5   2   7 
[1] Lactate dehydrogenase (LDH) was assessed at study entry as part of a battery of tests to assess liver function. A typical normal range is 105 to 333 Units/Liter (U/L), but may vary across laboratories.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression Free Survival (PFS)   [ Time Frame: Time from randomization to documented tumor progression or death (the maximum treatment duration of 71.1 weeks) ]

2.  Secondary:   Overall Survival (OS)   [ Time Frame: Time from randomization to death (the maximum treatment duration of 71.1 weeks) ]

3.  Secondary:   Number of Participants in Tumor Response Categories   [ Time Frame: Every 6 weeks from the start of the treatment until the end of treatment visit with a median of 134 days ]

4.  Secondary:   Time to Progression (TTP)   [ Time Frame: Time from randomization to documented tumor progression (median time of 148 days) ]

5.  Secondary:   Duration of Response (DOR)   [ Time Frame: Time from initial response to documented tumor progression or death (median time of 188 days) ]

6.  Secondary:   Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to the Visit When the Best Tumor Response Was Noted   [ Time Frame: Baseline and every 6 weeks from the start of the treatment until the end of treatment visit with a median of 134 days ]

7.  Secondary:   Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the Visit at Which Best Response Was First Noted   [ Time Frame: Baseline and every 6 weeks from the start of the treatment until the end of treatment visit with a median of 134 days ]

8.  Secondary:   Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the End of Treatment   [ Time Frame: Baseline and every 6 weeks from the start of the treatment until the end of treatment visit with a median of 134 days ]

9.  Secondary:   Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the Visit at Which Best Response Was First Noted   [ Time Frame: Baseline and every 6 weeks from the start of the treatment until the end of treatment visit with a median of 134 days ]

10.  Secondary:   Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the End of Treatment   [ Time Frame: Baseline and every 6 weeks from the start of the treatment until the end of treatment visit with a median of 134 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Therapeutic Area Head
Organization: BAYER
e-mail: clinical-trials-contact@bayerhealthcare.com


Publications of Results:

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00110994     History of Changes
Other Study ID Numbers: 11715
Study First Received: May 16, 2005
Results First Received: January 26, 2011
Last Updated: May 13, 2015
Health Authority: United States: Food and Drug Administration